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Introduction
Hepatitis E virus (HEV) is the most frequent cause of acute
hepatitis and has become an important public health
concern in many developing countries.1 Hepatitis E virus
is a non-enveloped, single-stranded ribonucleic acid
(RNA) virus that is approximately 27-34nm in diameter. It
has four genomes; genomes one and two are highly
virulent as well as prevalent in Asia.2 In Pakistan, the first
reported explosive water-borne epidemics of hepatitis E
was in Islamabad in 1994 followed by an outbreak in army
garrison in Lahore and then in Karachi.3 It is usually
transmitted through faecal contamination in water,
however, pig's internal organ and rodents were also
reported to be the means of transmission of disease in
sporadic cases in industrialised nations.4,5 A study
conducted by Khuro et al. also claims trans-placental
transmission of virus to the foetus.6
Hepatitis E presentation is similar to hepatitis A virus
including lethargy, anorexia, abdominal pain, jaundice
and fever. The disease has a very mild course in men and
non-pregnant women. However, in pregnant women this
infection is particularly severe and leads to high fatality.7
The prevalence of hepatitis E infection during pregnancy
is high ranging from 47.4-84.3%.4,8 It seems to be due to
altered immune response, hormonal changes and
malnutrition. In fact, the exact mechanism is not well
comprehended.9
During pregnancy, especially in the third trimester, the
infection is worst. It may progress to coagulation defects,
fulminant hepatic failure (FHF) and encephalopathy. It
also increases pregnancy complications like preterm
labour, post-partum haemorrhage (PPH) and maternal
mortality.10
Maternal mortality ranges from 36-71%.4,10 In majority of
the cases, these women developed FHF, which accounts
for 28-70%,3,5,6 while coagulation defect occurs in 26-
79%.10,11 S. Shukla et al. observed 100 cases of hepatitis
and encountered 6 patients who developed hepatitis
encephalopathy; no one survived among them.12
Haemorrhage during and after delivery is also not
uncommon as its prevalence is 4% and 27%,
respectively.10 In contrast, the reports from Egypt, Europe
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Abstract
Objective: To compare adverse maternal and foetal outcome in pregnant women with hepatitis E immunoglobulin
M reactive versus non-reactive.
Methods: This retrospective study was conducted at the Aga Khan University Hospital, Karachi, and comprised
records of pregnant patients at any gestational age with clinical and biochemical evidence of hepatitis E from
January 2002 and December 2014. . Maternal and perinatal outcome of the subjects were analysed. SPSS 20 was
used for data analysis.
Results: Out of the 200 subjects, 168(84 %) were hepatitis E immunoglobulin M reactive and 32(16%) were non-
reactive. The overall mean age was 26.7±4.5 years. Also, 12(7%) patients in the immunoglobulin M reactive group
were admitted to intensive care unit compared to no one from the non-reactive group. Similarly fulminant hepatic
failure was seen in 12(7.1%) patients in the immunoglobulin M reactive group compared to no one in the other
group. Post-partum haemorrhage was more frequent in the immunoglobulin M reactive group compared to the
non-reactive group. There were 5(3%) maternal deaths in the reactive group compared to no death in the other
group.
Moreover, 34(20.2%) neonates of the immunoglobulin M reactive group needed neonatal intensive care unit
admission compared to none in the non-reactive group. There were 4(2.4%) neonatal deaths in the reactive group.
Conclusion: Participants in the immunoglobulin M reactive group had a higher percentage of adverse foeto-
maternal outcomes compared to the non-reactive group.
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and the United States show no difference in severity of
the disease in non-pregnant and pregnant women.8,13
Perinatal mortality ranges from 5-20%.10,14 The rate of
intrauterine death (IUD) is around 5% while neonatal
death (NND) occurs in 8% of cases. This could be due to
disease itself or prematurity in more than 50% of cases.10
The current study was planned to compare maternal and
foetal outcome in pregnant women with hepatitis E
immunoglobulinM (IgM) reactive versus IgM non-reactive
presenting.
Materials and Methods
The study was conducted at the Department of Obstetrics
and Gynaecology in collaboration with the Department of
Gastroenterology at the Aga Khan University Hospital
(AKUH), Karachi, and comprised records of pregnant
women who developed jaundice and hepatitis E from
January 2002 to December 2014. The AKUH is one of the
largest tertiary hospitals in the private sector, with more
than 4,500 deliveries per annum. Approval for the study
was obtained from ethics review board of the institution.
Patients presenting with jaundice, serum bilirubin
>2.5mg/dl, increase in serum transaminases more than
twice than normal with reactive hepatitis E
immunoglobulin G (IgG) and IgMwere included.Women -
diagnosed with haemolysis, elevated liver enzymes, low
platelet count (HELLP) syndrome, obstetric cholestasis
and positive hepatitis A, B or C were excluded.
Participants were managed according to the
management protocol of the institution.
The study variables were age, parity and gestational age
at the time of presentation, mode of delivery,
complications related to hepatitis E and obstetric
complications along with maternal and foetal outcome.
Liver function test including alanine aspartate
aminotransferases,10 alanine aminotransferases (ALT),
alkaline phosphatase, bilirubin, complete blood count
(CBC), blood urea nitrogen (BUN) and creatinine and
prothrombin time (PT) were also noted.
Participants were divided into two groups; group A
included all women who were IgM reactive, while group B
comprised women who had IgM non-reactive but IgG
reactive for hepatitis E. Women were labelled as having
acute liver failure if they developed severe acute liver
injury with impaired liver function test and hepatic
encephalopathy within four weeks of onset which is
characterised by mental changes progressing from
confusion to stupor and coma as a result of severe
impairment of hepatic function, without any history of
pre-existing liver disease.15
SPSS 20 was used for data analysis. Mean and standard
deviation (SD) were calculated for continuous variables,
such as maternal age, gestational week at delivery, birth
weight of baby, biochemical test, etc. Frequency and
proportions were calculated for categorical variables,
such asmode/type of delivery, admission to intensive care
unit (ICU), occurrence of PPH, etc. Differences between
means were checked through t-test and association
between categorical/nominal variable was assessed
through chi-square/ Fisher's exact test as appropriate.
P<0.05 was considered significant.
Results
Of the 50,037 deliveries during the study period,
200(0.4%) pregnant women developed presented with
jaundice and positive hepatitis E antibodies and they
comprised the study sample. Of them, 95(47.5%) were
aged 25-30 years, 64(32%) were aged below 25 years and
41(20.5%) were aged above 30 years. The overall mean
age was 26.7±4.5 years. Moreover, 112(56%) subjects
were primigravidas.
In 159(80%) cases, the baby was delivered after 34 weeks'
gestation. Besides, 193(96.5%) participants presented in
the third trimester, whereas 183(91.5%) came to the
hospital in stable condition. Also, 115(57.5%) participants
had lower segment caesarean section (LSCS). There was
intrauterine foetal death in 11(5.5%) cases. Out of the
189(94.5%) patients whose foetuses were alive at the time
of admission, 4(2.1%) died in the neonatal period. In
addition, 34(17%) neonates needed neonatal intensive
care unit (NICU) admission.
Furthermore, 16(8%) patients had PPH and 2(1%) had
prolonged labour. Moreover, 12(6%) participants had FHF
and 2(1%) had hepatic encephalopathy. Besides, 12(6%)
required ICU admission while 86(43%) were admitted to
high dependency unit (Table-1).
The mean bilirubin level was 8.12±5.1 and 8.25±6.5in IgM
reactive and non-reactive group, respectively; the
difference was not significant. In regard to the values of
SGPT, SGOT, Alkaline phosphatase, GGT PT, APTT and INR
the data was skewed therefore median value and range
was calculated (Table-2).
There were 168(84%) participants in the IgM reactive
group compared to 32(16%) in the non-reactive group.
Moreover, 76(45.2%) participants in the IgM reactive
group were in the age group of 25-30 years compared to
19(59.4%) in the non-reactive group (p=0.34). In the IgM
reactive group, 98(58.3%) were primigravidas compared
to 14(43.8%) in the IgM non-reactive group (p=0.09).
Gestational age at delivery was significantly different in
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both the groups. All patients in the IgM non-reactive
group were more than 34 weeks compared to 127(75.6%)
in the IgM reactive group (p=0). On arrival 16(9.5%)
patients were unstable in the IgM reactive group
compared to 1(3.1%) in the other group (p=0.20). Also,
102(60.7%) patients in the IgM reactive group underwent
LSCS compared to 13(40.6%) in the non-reactive group
(p=0.02). The number of intrauterine deaths was 9(5.4%)in
the reactive group vs. 2(6.3%) in the non-reactive group.
Moreover, 34(20.2%) neonates in the IgM reactive group
needed NICU admission while not a single neonate from
the IgM non-reactive group required admission in NICU.
There were 4(2.4%) neonatal deaths in the IgM reactive
group compared to none in the other group.
Besides, 12(7%) patients in the IgM reactive group were
admitted to ICU compared to no one from the IgM non-
reactive group. Similarly, FHF was seen in 12(7.1%)
patients in the IgM reactive group while no one in the
other group developed FHF. PPH was more frequent in
Vol. 67, No. 4, April 2017
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Table-1: Characteristics of patients infected with hepatitis E.
Variables F r e q u e n c y
(%)
Age Mean ± SD 26.7±4.5
< 25 Years 64 (32.0)
25-30 Years 95 (47.5)
> 30 Years 41(20.5)
Gravida
PrimiGravida 112 (56.0)
Multi Gravida 88 (44.0)
Gestational age at delivery
< 34 41(20.5)
> = 34 159 (79.5)
Trimester
II Trimester 7 (3.5)
III Trimester 193 (96.5)
Patient condition on arrival
Stable 183 (91.5)
Unstable 17 (8.5)
Mode of delivery
SVD 78 (39.0)
LSCS 115 (57.5)
Not deliver in AKU 7 (3.5)
Condition of foetus on arrival
Alive 182 (91.0)
Dead 11(5.5)
Not deliver in AKU 7 (3.5)
Condition of baby at the time of delivery
Alive 178 (89.0)
IUD 11(5.5)
NND 4 (2.0)
Not deliver in AKU 7 (3.5)
NICU admission *
No 148 (78.3)
Yes 34 (17.8)
Not deliver in AKU 7 (3.7)
Complications due to hepatitis
Fulminant hepatic failure 12 (6.0)
Hepatic encephalopathy 2 (1.0)
No complication 186 (93.0)
Complication during labour
PPH 16 (8.0)
Prolong labour 2 (1.0)
Others 12 (6.0)
No complication 170 (85.0)
ICU/Special care admission
No 102 (51.0)
Yes 12 (6.0)
Special care 86 (43.0)
Maternal Outcome
recovered and discharged 195 (97.5)
Died 5 (2.5)
*IUDs were excluded from the denominator (n; 189)
SVD: Spontaneous vaginal delivery. LSCS: Lower segment caesarean section.
AKU: Aga Khan University. IUD: Intrauterine death.
NND: Neonatal death. NICU: Neonatal intensive care unit.
ICU: Intensive care unit. PPH: Post-partum haemorrhage.
SD: Standard deviation.
Table-2: Analysis of laboratory parameters in Hepatitis E, IgM reactive and IgM non-
reactive.
Laboratory IgM reactive IgM non- reactive P value
parameters Mean ± S.D Mean ± S.D
Bilirubin 8.12±5.1 (mg/dl) 8.25±6.5 0.272
Direct 5.24±2.7 (mg/dl) 6.0±3.5 0.223
Indirect 3.40±2.4 (mg/dl) 4.72±2.9 0.597
SGPT 264.5 IU/L(120-2690) 270.5(100-2015) *
SGOT 219.0 IU/L(105-4038) 333.0(102-2760) *
Alkaline phosphatase 214.5 IU/L(102-1140) 207.0(140-499) *
GGT 28.0 IU/L(4-129) 28.0(10-102) *
PT 11.3(10-70) Seconds 12.3(11-70) *
APTT 27.5(11.0-150.0) Seconds 30.2(20.4-47.7) *
INR 1.27(0.80-11.0) Ratio 1.04(0.94-6.6) *
HB 10.9±1.1 g/dl 11.3±1.5 0.238
HCT 32.5±3.8% 33.0±5.6 0.387
RBC 3.8±0.4* 10 E12/L 4.2±0.7 0.524
WBC 13.5±5.8* 10E9/L 14.7±10.2 0.383
Neutrophils 66.4±13.1% 71.9±12.8 0.520
Platelets 271.7±125.3 10E9/L 239.±89.7 0.447
*Median (Range)
IgM: Immunoglobulin M
SGPT: Serum glutamic-pyruvic transaminase
SGOT: Serum glutamic oxaloacetic transaminase
GGT: Gamma-glutamyltransferase
PT: Prothrombin time
APTT: Activated partial thromboplastin time
INR: International normalized ratio
HB: Haemoglobin
HCT: Haematocrit
RBC: Red blood cells
WBC:White blood cells
BUN: Blood urea nitrogen.
the IgM reactive group compared to the IgM non-reactive
group. There were 5(3%) maternal deaths in the IgM
reactive group compared to no death in the other group
(Table-3).
Discussion
The frequency of hepatitis E was found to be 0.4% in the
current study, similar to a study conducted by Sharda
Patra that showed overall frequency of jaundice among
pregnant women to be 0.6%, out of which 60% were
suffering from hepatitis E.11 However, another study
conducted in Chennai, India, demonstrated that only
0.11% deliveries presented with jaundice, out of which
two-thirds were due to hepatitis E.16
The overall mean age was 26.7±4.5 years in the current
study, with majority of the participants aged below 30
years. Another study conducted in Pakistan showed a
mean age of 26.4 years.17
In our study, more than half of the participants were
primigravidas, which is consistent with studies by Shresta
et al. and Shukla et al.10,12
Majority of patients in our study were in their third
trimester, with gestational age being more than 34 weeks
in 79.5% cases. This is comparable to other studies done in
South Asia in which majority of patients presented in the
third trimester.10,11
Babies in more than half of the cases were delivered by
lower segment caesarean section; this finding is similar to
a study conducted in Pakistan.18 In contrast, another
study by Tahira et al. shows only 9% babies were delivered
by lower segment caesarean section.19 However, both the
above-mentioned studies had small sample size of 30-33
patients, hence it would be difficult to draw any definitive
conclusions.
In our study, the most common maternal complication
associated with hepatitis E was PPH (8%); this can be
attributed to the deranged coagulation present as part of
the disease process. This frequency was found to be
between 14-27% in other studies.10,11 This may be due to
the routine practice of prophylactic transfusion of fresh
frozen plasma and cryoprecipitate just before delivery to
avoid bleeding.
Two of our patients developed hepatic encephalopathy,
however, both survived. Moreover, 7.1% developed FHF.
In other studies the rate of FHF was very high ranging
from 55-82%.1,11 Literature strongly suggests that
pregnant womenwith acute hepatitis E are more prone to
develop FHF than non-pregnant and men.20 However,
once FHF develops, its prognosis is similar to non-
J Pak Med Assoc
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Table-3: Comparison of clinical parameters in Hepatitis E, IgM reactive and IgM
nonreactive.
Variables IgM reactive IgM non-reactive P value
N 168(%) N 32(%)
Age 0.34
<25 years 56(33.3) 8(25)
25-30years 76(45.2) 19(59.4)
>30 years 36(21.4) 5(15.6)
Gravida 0.09
Primigravida 98(58.3) 14(43.8)
Multigravida 70(41.7) 18(56.3)
Gestational age at the time of delivery 0
<34 41(24.4) 0(0)
>=34 127(75.6) 32(100)
Trimester 0.28
2nd trimester 7(4.2) 0(0)
3rd trimester 161(95.8) 32(100)
Patient condition on arrival 0.2
Stable 152(90.5) 31(96.9)
Unstable 16(9.5) 1(3.1)
Mode of delivery 0.02
SVD 59 (35.1) 19(59.4)
LSCS 102(60.7) 13(40.6)
Not delivered in AKU 7(4.2)
Condition of baby at the time of delivery 0.52
Alive 148(88.1) 30(93.8)
IUD 9(5.4) 2(6.3)
NND 4(2.4) 0(0)
Not delivered in AKU 7(3.5)
NICU admission* 0.007
No 118 (74.2) 32(100)
Yes 34(21.4) 0(0)
Not delivered in AKU 7(4.4)
Complications due to hepatitis 0.092
Fulminant Hepatic failure 12(7.14) 0(0)
Hepatic Encephalopathy 2(1.2) 0(0)
Others 0(0) 1(3.1)
No Complication 154(91.7) 31(96.9)
Complication during labour 0.66
PPH 14(8.3) 1(3.1)
Prolong labour 2(1.2) 0(0)
APH 1(0.6) 0(0)
Others 5(3.0) 2(6.3)
No complication 146(86.9) 29(90.6)
ICU 0.06
special Care 12(7.1) 0(0)
Yes 67(39.9) 19(59.4)
Ward 89(53.0) 13(40.6)
Maternal Out come 0.41
Recovered and discharged 163(97) 32(100)
Died 5(3) 0(0)
*IUDs were excluded from the denominator (n; 159)
IgM: Immunoglobulin M. SVD: Spontaneous vaginal delivery.
LSCS: Lower segment caesarean section. AKU: Aga Khan University.
IUD: Intrauterine death. NND: Neonatal death.
NICU: Neonatal intensive care unit. ICU: Intensive care unit.
PPH: Post-partum haemorrhage. APH: Antepartum haemorrhage.
pregnant patients.21
In our study, 11 patients had intrauterine foetal demise on
presentation, while there were four neonatal deaths. Also,
17% neonates required intensive care admission. Most of
the babies (80%) were healthy and discharged in
satisfactory condition. Other studies show higher rate of
stillbirth of 54% and the rate of take-home babies was just
21%.11 This discrepancy may be due to advance
gestational age in our data set and better neonatal
services.
In our study, 17% participants were unstable at initial
presentation out of which one woman was negative for
IgM, but positive for IgG antibodies of hepatitis E.
Nevertheless, literature supports that IgM positive
suggests acute infection while IgG positive implies
convalescence phase. This drew our attention to divide
our dataset in IgM positive and IgM negative groups to
compare the morbidity. We had 200 women presented
with jaundice, out of which 84% were IgM positive while
only 16% were IgM negative. Two African studies also
enrolled both IgM and IgG positive groups.14,22 In our
study, gestational age was more than 34 weeks among all
women who were IgM negative and12% of the IgM
positive women. Modes of delivery between both these
groups were significantly different, as more babies in the
IgM positive group were delivered by Caesarean section.
With regard to complications, women in the IgM positive
group had more complications like haemorrhage, hepatic
encephalopathy and FHF. There was special care
admission in 59% of women with IgM negative and
jaundice and none required ICU care.
Previous studies in Pakistan have shown high maternal
mortality of 29.3%19 and 35%17 with hepatitis E. Other
studies from our region show similar data with maternal
mortality of 32.6% reported by Shinde N.R. et al from
India.23 In our study, overall maternal mortality was 2.5%,
with 96.5% patients presenting in the 3rd trimester, out of
which 12 had FHF and 5 died. We attribute this low
mortality to timely and proactive multidisciplinary
approach involving obstetricians, gastroenterologists,
anaesthetists and intensivists. Delivery was expedited in
all our patients. Though there is conflicting evidence
regarding benefit of early delivery in reducing maternal
mortality, immediate delivery was the standard of care in
our study.
Studies done in Egypt and America show a much milder
course of hepatitis E in pregnancy disease, probably due
to different genotypes of the disease in industrialised
countries.8,13,22
The current study was the first in the South Asian region
involving pregnant women with hepatitis E with a sample
size of 200 and conducted over a period of 12 years.
However, one of the limitations of the study was its
retrospective nature. The authors have already planned to
conduct a prospective study to address the shortcomings
of the current study.
Recently, M. Khuroo postulated a possible mechanism to
explain the increased severity of the disease in pregnancy.
The author suggested that vertical transmission of
infection to the developing foetuses causes production of
toxic metabolites, which worsens the disease in the
mother.24
In the start of 2015, results of hepatitis E vaccination
phase-three trial were published, showing efficacy of 85%
with sustained protection for 4.5 years.25 In India 300
million people still defecate in the open, though this is not
the case in a big metropolitan city like Karachi,
nonetheless mixing of water and sewerage lines does
commonly occur increasing the chances of being infected
with hepatitis E. It is estimated that 1.8 billion people
consume faecally contaminated water globally.24 The
government needs to take the initiative to make safe and
clean drinking water accessible to everyone. Furthermore,
the disease burden can be reduced by the availability of
hepatitis E vaccine, especially to pregnant women.
Conclusion
Participants in the IgM reactive group had a higher
percentage of adverse foeto-maternal outcomes
compared to the ones in IgM non-reactive group.
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